Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.40
−$0.09 · -3.61%
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Latest quote
$2.40
−$0.09 · -3.61%
After-hours
$2.27
−$0.13 · -5.42%
Oct 9, 7:39 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
22
Expensive
Sentiment
59
Mixed
Risk
79
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Day range
Current $2.40
52-week range
Current $2.40
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 4, 2026 | 1:25 | — | — |
Stock split | Jun 12, 2025 | 1:15 | — | — |
Stock split | Oct 17, 2022 | 1:20 | — | — |
Stock split | Mar 26, 2021 | 1:2 | — | — |
Stock split | Jun 17, 2016 | 1:50 | — | — |
Effective May 4, 2026
1:25
Effective Jun 12, 2025
1:15
Effective Oct 17, 2022
1:20
Effective Mar 26, 2021
1:2
Effective Jun 17, 2016
1:50
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
